US Stock MarketDetailed Quotes

LENZ LENZ Therapeutics

Watchlist

17.540
-0.150-0.85%

Close Jul 2 16:00 ET

447.87MMarket Cap-1419P/E (TTM)

LENZ Therapeutics Stock Forum

70994532

Apr 17 17:43

$LENZ Therapeutics(LENZ.US)$ $NVIDIA(NVDA.US)$
Why the April 19 call option strike @$5 costs only $0.05?

hard-working Camel_4

Apr 1 21:10

$LENZ Therapeutics(LENZ.US)$ $Graphite Bio(GRPH.US)$
moomoo is very funny, they admitted their display error on the ex dividend date. Then say "the advisory information doesn't serve as investments advice, we are unable to compensate for the economic losses you mentioned"
the story is Moomoo put the wrong ex dividend date causing his clients to sell before the actual ex dividend date then tell clients that " the advisory information doesn't serve as investments advice, so unable to compensate".
...

_komodo_

Mar 27 10:36

$LENZ Therapeutics(LENZ.US)$ my situation is weird: they sent my dividend in 21 Mar, but today 26 Mar they withdraw. Any one know this issue?

amiable Hedgehog_758

Mar 27 06:10

$LENZ Therapeutics(LENZ.US)$ hi we need to do class action I didn’t got the dividend they owe me 3,000$

hard-working Camel_4

Mar 26 08:43

$LENZ Therapeutics(LENZ.US)$ anyone can help? I sell $Graphite Bio(GRPH.US)$ on ex dividend date which is 15th but still haven't get dividends yet

hard-working Camel_4

Mar 26 08:32

$LENZ Therapeutics(LENZ.US)$ who haven't get dividends one? we need report to moomoo

hard-working Camel_4

Mar 26 04:11

$LENZ Therapeutics(LENZ.US)$ where is the dividend for $Graphite Bio(GRPH.US)$

Moomoo AI

Mar 25 15:09

Dr. Rizvi's appointment, with his vast experience in cancer treatments, is a major asset to Poseida Therapeutics. His expertise will be crucial as the company progresses its clinical stage CAR-T portfolio.

Press Release: Poseida Therapeutics Appoints Syed Rizvi, M.D., as Chief Medical Officer

Learntogain

Mar 25 13:18

$LENZ Therapeutics(LENZ.US)$ anbody recieved special dividend?

Trytosaveabit

Mar 25 06:51

Update

$LENZ Therapeutics(LENZ.US)$ Allarity Therapeutics Has Been Granted A Formal Extension Until April 24, 2024 To Regain Compliance Under Nasdaq Listing Rules

No comment yet

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall